Affinage

STC2

Stanniocalcin-2 · UniProt O76061

Audit flag: ungrounded claim
Length
302 aa
Mass
33.2 kDa
Annotated
2026-06-10
64 papers in source corpus 25 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

STC2 is a secreted glycoprotein that regulates extracellular growth-factor signaling, mineral handling, and tissue growth, and is repeatedly co-opted as a downstream oncogenic effector in multiple cancers (PMID:9753616, PMID:27662663, PMID:42217552). Its best-resolved biochemical activity is as a covalent inhibitor of the metalloprotease PAPP-A: STC2 forms a 2:2 heterotetramer with PAPP-A by binding exosites distal to the catalytic cleft, sterically blocking IGFBP substrate engagement and cleavage (PMID:36550107). Independently of this protease control, conditioned medium from STC2-expressing cells suppresses Na-phosphate cotransporter promoter activity and renal phosphate uptake, an activity opposite to STC1 (PMID:9753616), and a conserved A60P missense variant in gene-edited mice increases body weight, establishing a causal role in mammalian growth regulation (PMID:40094447). In physiological contexts STC2 suppresses adipogenic differentiation of mesenchymal stem cells through ERK1/2 activation and PPARγ/FABP4 repression (PMID:31982135) and is required for sensory axon regeneration after injury (PMID:33011858). Across cancers STC2 acts upstream of converging pro-tumorigenic pathways—PI3K/AKT/(mTOR), ERK/MAPK, Wnt/β-catenin, and the JUN–AXL–ERK axis—to drive EMT, glycolysis, proliferation, survival, and therapy resistance (PMID:27662663, PMID:27863406, PMID:31173256, PMID:31162839, PMID:39271096, PMID:41843816). STC2 expression is itself directly transactivated by HIF-1α under hypoxia (PMID:42217552, PMID:41408929), by HMGA2 (PMID:26165228, PMID:35353897), by ATF4 (PMID:41274065), and by STAT3 (PMID:41203580), and is stabilized post-transcriptionally by METTL3-dependent m6A modification read by YTHDF2 (PMID:40494964, PMID:40499413). STC2 also engages intracellular and RNA-level effectors: it interacts with and activates PRMT5 to increase H4R3me2s and promote DNA-damage repair and ferroptosis suppression (PMID:36764215), binds and stabilizes TGIF1 mRNA to promote anoikis resistance (PMID:41696444), and stabilizes SQSTM1 protein to enhance mitophagy (PMID:40499413).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 1998 Medium

    Established STC2 as a secreted glycoprotein with an endocrine-like activity on mineral handling, distinguishing it functionally from its paralog STC1.

    Evidence Molecular cloning with CHO conditioned-medium transfer onto kidney OK cells, NaPi-3 promoter reporter and phosphate-uptake assays

    PMID:9753616

    Open questions at the time
    • No receptor or direct molecular target for the phosphate effect identified
    • Endogenous physiological context untested
  2. 2012 Medium

    Showed STC2 drives cell-cycle progression and proliferation through cyclin D1 and ERK1/2, the first link to a proliferative cancer phenotype.

    Evidence Ectopic expression and siRNA in hepatocellular carcinoma cells with cell-cycle flow cytometry and pathway Western blots

    PMID:23187001

    Open questions at the time
    • Mechanism by which secreted STC2 activates ERK1/2 not defined
    • No receptor identified
  3. 2015 Medium

    Identified an upstream transcriptional regulator (HMGA2) of STC2 and tied STC2 to invasion, beginning to map the regulatory circuitry controlling its expression.

    Evidence Transcriptional regulation assays plus migration/invasion assays, with correlation across three patient cohorts

    PMID:26165228

    Open questions at the time
    • Direct promoter binding by HMGA2 not structurally mapped
    • Downstream effectors of invasion unresolved here
  4. 2016 Medium

    Placed STC2 upstream of PI3K/AKT and ERK signaling as a sufficient inducer of EMT, and as a downstream effector of Mus81, integrating it into proliferation/survival circuitry.

    Evidence Overexpression, exogenous protein, pharmacological pathway inhibition and Mus81 rescue in colorectal and HCC models with xenografts

    PMID:27662663 PMID:27939696

    Open questions at the time
    • How extracellular STC2 transmits signal to intracellular kinases unresolved
    • Direct binding partners not identified
  5. 2019 Medium

    Extended STC2 oncogenic signaling to the JUN–AXL–ERK axis and Wnt/β-catenin, explaining its role in acquired EGFR-TKI resistance and EMT.

    Evidence AXL promoter luciferase, phospho-c-Jun blots, pharmacological rescue (SB216763) and patient-derived resistant cells

    PMID:31162839 PMID:31173256

    Open questions at the time
    • Mechanism linking secreted STC2 to c-Jun phosphorylation unknown
    • Receptor mediating Wnt pathway control not defined
  6. 2020 Medium

    Defined non-cancer physiological roles—suppression of adipogenesis via ERK1/2 and a requirement in injury-induced axon regeneration—broadening STC2 beyond tumor biology.

    Evidence Gain/loss-of-function with ERK inhibitor rescue in hMSCs; axotomy transcriptomics, exogenous protein and AAV delivery in DRG neurons in vivo

    PMID:31982135 PMID:33011858

    Open questions at the time
    • Receptor for secreted STC2 in either context unidentified
    • Signaling intermediates in neurons unmapped
  7. 2022 High

    Resolved the central biochemical mechanism: STC2 is an exosite-competitive covalent inhibitor of PAPP-A that blocks IGFBP cleavage, providing a structural basis for its growth-regulatory activity.

    Evidence Cryo-EM of the endogenous PAPP-A/STC2 heterotetramer with IGFBP linker peptide functional assays

    PMID:36550107

    Open questions at the time
    • Links between this PAPP-A inhibition and the downstream oncogenic kinase signaling not established
    • In vivo consequences of inhibition not quantified here
  8. 2023 Medium

    Revealed an intracellular activity—STC2 binds and activates PRMT5 to increase H4R3me2s—coupling STC2 to DNA-damage repair, ferroptosis suppression and radioresistance.

    Evidence Reciprocal Co-IP, H4R3me2s blots, siRNA and xenografts in esophageal squamous cell carcinoma

    PMID:36764215

    Open questions at the time
    • How a classically secreted protein accesses nuclear PRMT5 unresolved
    • Direct STC2-PRMT5 binding interface unmapped
  9. 2025 Medium

    Mapped the upstream transcriptional and post-transcriptional control of STC2—HIF-1α, ATF4, STAT3 and METTL3/YTHDF2 m6A—and a causal growth role via the A60P mouse variant, consolidating how STC2 levels are set across stress and disease states.

    Evidence ChIP/dual-luciferase for HIF-1α and ATF4 promoter binding, MeRIP-seq for m6A, gene-edited A60P knock-in mice, plus fibrosis, asthma, calcification and glioma models

    PMID:40094447 PMID:40126711 PMID:40494964 PMID:40499413 PMID:41203580 PMID:41274065 PMID:41408929

    Open questions at the time
    • ITGB2 and STAT3 links rest on single Co-IP/transcriptomic evidence
    • Unifying receptor for STC2 signaling still unidentified
  10. 2026 Medium

    Detailed STC2's metabolic and RNA-stabilizing outputs—PI3K/AKT/mTOR-driven c-Myc activation of glycolytic gene promoters and direct stabilization of TGIF1 mRNA—linking it to glycolysis, M2 macrophage polarization and anoikis resistance.

    Evidence ChIP for c-Myc on GLUT1/LDHA promoters, RIP and RNA-stability assays, glucose/lactate assays and xenografts in CRC and HCC

    PMID:41696444 PMID:41843816 PMID:42217552

    Open questions at the time
    • Whether STC2 directly binds RNA or acts via partners not fully resolved
    • Connection between extracellular and RNA-binding pools of STC2 unexplained

Open questions

Synthesis pass · forward-looking unresolved questions
  • The receptor or surface mechanism by which secreted STC2 transduces signals into PI3K/AKT and ERK pathways, and how a secreted protein reaches intracellular/nuclear targets (PRMT5, TGIF1 mRNA, SQSTM1), remain unresolved.
  • No STC2 signaling receptor identified in the corpus
  • Subcellular trafficking reconciling secreted and intracellular roles unknown
  • Causal link between PAPP-A inhibition and downstream kinase signaling untested

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 2 GO:0003723 RNA binding 1 GO:0098772 molecular function regulator activity 1
Localization
GO:0005576 extracellular region 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-1430728 Metabolism 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1643685 Disease 2
Partners
ITGB2PAPPAPRMT5TGIF1
Complex memberships
PAPP-A/STC2 heterotetramer

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1998 STC2 (stanniocalcin-2) encodes a secreted glycoprotein with 34% identity to STC1; conditioned medium from STC2-transfected CHO cells inhibited the promoter activity of the Na-phosphate cotransporter (NaPi-3) and inhibited phosphate uptake in kidney OK cells, demonstrating an inhibitory function on renal phosphate transport opposite to STC1. Molecular cloning, CHO cell transfection, NaPi-3 promoter reporter assay, phosphate uptake assay in OK cells Biochemical and biophysical research communications Medium 9753616
2022 STC2 forms a 2:2 heterotetramer with PAPP-A (pregnancy-associated plasma protein-A) via covalent interaction, revealed by cryo-EM structures. STC2 binds exosites on PAPP-A distal to its catalytic cleft, causing steric hindrance that prevents IGFBP substrate binding and cleavage, thus inhibiting PAPP-A protease activity toward IGFBPs. Cryo-EM structural determination of endogenous PAPP-A/STC2 complex; functional assays with IGFBP linker peptides Cell discovery High 36550107
2023 STC2 physically interacts with PRMT5 and activates it, leading to increased symmetric dimethylation of histone H4 on Arg3 (H4R3me2s), which promotes DNA damage repair via homologous recombination and NHEJ pathways; STC2 also participates in SLC7A11-mediated ferroptosis suppression in a PRMT5-dependent manner, contributing to radioresistance in esophageal squamous cell carcinoma. Co-immunoprecipitation (STC2-PRMT5 interaction), Western blot for H4R3me2s, siRNA knockdown, in vivo xenograft experiments Redox biology Medium 36764215
2019 STC2 promotes AXL promoter activity by increasing phosphorylation of c-Jun, an indispensable transcription factor for AXL transactivation, thereby activating the JUN-AXL-ERK signaling axis and conferring acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. AXL promoter luciferase reporter assay, phospho-c-Jun Western blot, genetic silencing/overexpression of STC2, pharmacological inhibition of AXL-ERK, patient-derived resistant cell line validation International journal of cancer Medium 31162839
2016 STC2 overexpression in colorectal cancer cells activates pERK, pAKT, PI3K and Ras signaling; blocking AKT-ERK signaling pathways attenuates STC2-activated EMT. Exogenous STC2 protein is sufficient to induce EMT characteristics in epithelial cells. STC2 plasmid transfection, exogenous STC2 protein treatment, Western blot for pathway markers, pharmacological pathway inhibition, mouse xenograft model Oncotarget Medium 27662663
2017 STC2 upregulates phosphorylation of AKT and enhances HNSCC metastasis through Snail-mediated increase of vimentin and decrease of E-cadherin (EMT markers); these effects are blocked by silencing STC2/Snail or inhibiting pAKT activity, placing STC2 upstream of the PI3K/AKT/Snail axis. STC2 overexpression/silencing, pAKT Western blot, Snail/vimentin/E-cadherin Western blot, in vivo metastasis assay, pharmacological AKT inhibition Oncotarget Medium 27863406
2015 HMGA2 directly regulates STC2 transcription; overexpression of STC2 in ovarian cancer cells directly enhances cell migration and invasion in vitro. Transcriptional regulation assay (HMGA2→STC2), in vitro migration/invasion assays, gene expression correlation in three independent patient cohorts Oncology reports Medium 26165228
2012 STC2 regulates cyclin D1 expression and activates ERK1/2 signaling in hepatocellular carcinoma cells to promote G0/G1 to S-phase cell cycle progression and cell proliferation. STC2 ectopic expression and siRNA knockdown, flow cytometry cell cycle analysis, Western blot for cyclin D1 and pERK1/2, colony formation and Transwell migration assays BMB reports Medium 23187001
2016 STC2 acts downstream of Mus81 to promote HCC cell proliferation and survival; Mus81 knockdown downregulates STC2, which in turn activates APAF1, APC, and PTEN pathways and inhibits the MAPK pathway; restoration of STC2 expression rescues proliferation and survival defects caused by Mus81 depletion. DNA microarray screening, high content screen, qRT-PCR, STC2 rescue expression, knockdown of Mus81 in vitro and in vivo Cancer letters Medium 27939696
2019 STC2 silencing in colorectal cancer SW480 cells activates the Wnt/β-catenin pathway (β-catenin expression suppressed by STC2 silencing and restored by Wnt activator SB216763), and STC2 silencing decreases MMP-2, MMP-9, and vimentin while increasing E-cadherin, indicating STC2 promotes EMT via Wnt/β-catenin signaling. STC2 siRNA knockdown, Western blot for β-catenin/E-cadherin/vimentin/MMP-2/MMP-9, pharmacological rescue with SB216763, wound healing/Transwell assays Molecular medicine reports Medium 31173256
2020 STC2 overexpression in human mesenchymal stem cells suppresses adipogenic differentiation by increasing ERK1/2 phosphorylation and decreasing PPARγ and FABP4 expression; treatment with ERK inhibitor U0126 disrupts ERK1/2 phosphorylation and restores adipogenic differentiation, placing STC2 upstream of ERK1/2 in adipogenesis suppression. STC2 overexpression/knockdown, adipogenic differentiation assay, lipid droplet staining, Western blot for ERK1/2 phosphorylation/PPARγ/FABP4, ERK inhibitor (U0126) rescue Biochemical and biophysical research communications Medium 31982135
2020 STC2 is required for axon regeneration in sensory neurons; STC2 expression is upregulated after axotomy in dorsal root ganglion neurons, and loss of STC2 impairs axon regeneration both in vitro and in vivo; application of secreted STC2 protein to injured DRG neurons promotes regeneration; in vivo gene delivery of STC2 increases regenerative growth after peripheral nerve injury. Injury-responsive transcriptome analysis, STC2 loss-of-function in vitro/in vivo, exogenous STC2 protein application, in vivo AAV-mediated gene delivery in mice Molecular neurobiology Medium 33011858
2022 HBV X protein (HBx) transcriptionally upregulates HMGA2, which in turn transcriptionally activates STC2; STC2 knockdown disrupts Bax/Bcl-2 balance, increases cytochrome c release and caspase 3/7 activity, abolishing HMGA2-driven growth promotion; STC2 acts as a cytoprotective downstream effector of the HBx/HMGA2 pathway to counteract oxidative stress-induced apoptosis. HBx overexpression, HMGA2 and STC2 siRNA knockdown, Western blot for Bax/Bcl-2/cytochrome c/caspase 3/7, ChIP or promoter assay implied by transcriptional regulation data, clinical correlation with serum samples Carcinogenesis Medium 35353897
2024 STC2 knockdown in HCC cells inhibits glycolysis (reducing PKM2, GLUT1, HK2 expression), induces autophagy (increasing LC3II/LC3I and Beclin1), and reduces PI3K/AKT/mTOR phosphorylation; glycolysis inhibitor (2-DG) blocks STC2-driven HCC growth, and autophagy/PI3K pathway modulators (3-MA, IGF-1, Rap, LY294002) alter STC2 effects, placing STC2 upstream of PI3K/Akt/mTOR-mediated autophagy and glycolysis. STC2 siRNA knockdown and overexpression, Western blot for glycolytic enzymes and autophagy markers, pharmacological modulators (2-DG, 3-MA, IGF-1, Rap, LY294002), in vivo xenograft Archives of biochemistry and biophysics Medium 39271096
2025 ATF4 transcription factor directly binds to the STC2 promoter region and upregulates STC2 transcription (along with OMD) in vascular smooth muscle cells; this ATF4→STC2 axis activates the PI3K/AKT signaling pathway, promoting osteogenic differentiation of HASMCs and vascular calcification; AAV-mediated ATF4 knockdown in vivo alleviates vascular calcification by suppressing STC2 expression. ChIP assay (ATF4 binding to STC2 promoter), luciferase promoter reporter assay, Western blot, in vitro osteogenic differentiation, in vivo AAV-SM22α-shATF4 mouse model Pathology, research and practice Medium 41274065
2025 In keloid fibroblasts, hypoxia induces STC2 expression via HIF-1α; STC2 silencing under hypoxia reduces fibroblast proliferation, migration and ECM remodeling (downregulating collagen I, α-SMA, MMP2, MMP9) and attenuates ERK and AKT signaling pathway activation. HIF-1α pathway analysis, STC2 siRNA silencing under hypoxic conditions, Western blot for fibrosis markers and pERK/pAKT, functional proliferation and migration assays Experimental dermatology Medium 41408929
2025 METTL3 (m6A methyltransferase) upregulates STC2 mRNA stability through m6A modification (primarily in CDS region) via YTHDF2 binding; STC2 overexpression drives glycolysis-related enzyme expression, CRC cell proliferation and metastasis; METTL3 knockdown reduces 5-FU resistance and these effects are reversed by STC2 overexpression. MeRIP-seq, mRNA-seq, Western blot, EdU, CCK-8, Transwell assay, siRNA knockdown and overexpression, in vivo xenograft Cell biology and toxicology Medium 40494964
2025 METTL3-mediated m6A methylation of STC2 mRNA increases its stability via YTHDF2 binding in response to PM2.5 exposure; STC2 in turn increases SQSTM1 levels by inhibiting its proteasomal degradation, thereby enhancing mitophagy and asthma severity. Single-cell RNA sequencing, m6A methylation analysis, METTL3/STC2 knockdown, SQSTM1 protein stability assay, in vivo asthma mouse model Journal of hazardous materials Medium 40499413
2026 STC2 binds TGIF1 mRNA directly (via RNA immunoprecipitation) and stabilizes it by inhibiting its degradation; this mechanism enables STC2 to promote anoikis resistance in colorectal cancer cells through upregulation of TGIF1 expression. RNA immunoprecipitation (RIP), RNA stability assay, RNA sequencing, flow cytometry (anoikis), live/dead staining Frontiers in cell and developmental biology Medium 41696444
2025 STC2 interacts with ITGB2 (integrin beta-2) in glioma cells (confirmed by co-immunoprecipitation); STC2 knockdown inhibits glioma cell proliferation, invasion, migration, and glycolysis, and ITGB2 knockdown phenocopies these effects; the STC2/ITGB2 interaction is required for STC2-mediated regulation of these processes. Co-immunoprecipitation (STC2-ITGB2), GPIA database analysis, CCK-8, colony formation, Transwell, ELISA, Western blot Metabolic brain disease Low 40126711
2026 STC2 promotes glycolysis and CRC progression through the PI3K/AKT/mTOR pathway, which enhances c-Myc activity; activated c-Myc directly occupies GLUT1 and LDHA promoters (shown by ChIP) to upregulate glycolytic flux; STC2 knockdown reduces c-Myc occupancy on these promoters. ChIP for c-Myc on GLUT1/LDHA promoters, glucose uptake and lactate production assays, Western blot, STC2 KD/OE, in vivo xenograft Discover oncology Medium 41843816
2025 Nicotine activates the JAK2/STAT3 signaling pathway through CHRNA5, causing direct STAT3 binding to the STC2 promoter and upregulating STC2 transcription; STC2 subsequently upregulates TGFBI, which interacts with ITGA5 on endothelial cells to regulate vascular permeability; STC2 knockdown alters F-actin cytoskeletal dynamics by modulating small GTPase signaling. Spatial transcriptomics, scRNA-seq, STAT3 promoter binding assay (STAT3→STC2), STC2 knockdown, F-actin cytoskeleton analysis Advanced science Low 41203580
2025 In cancer-associated fibroblasts, STC2 depletion prevents CAF alignment and blocks multicellular calcium wave-driven neuronal mimicry, thereby reducing immune exclusion and allowing CD8+ T cell access to tumor cells. STC2 depletion (molecular intervention), CAF alignment assay, calcium imaging, CD8+ T cell localization analysis in tumor model bioRxivpreprint Low
2025 A missense mutation A60P in the conserved region of STC2 (validated in gene-edited mouse models) results in homozygous carriers with approximately 11% increased average body weight, establishing that the STC2 protein influences mammalian body size/growth regulation. Gene-edited mouse models with STC2 A60P knock-in, body weight measurement Genomics, proteomics & bioinformatics Medium 40094447
2026 HIF-1α directly binds to the STC2 promoter and activates STC2 transcription under hypoxic conditions in hepatocellular carcinoma cells (demonstrated by ChIP and dual-luciferase reporter assay); STC2 overexpression activates the PI3K-Akt and HIF-1α signaling pathways and is associated with M2-type macrophage polarization in the tumor microenvironment. ChIP assay and dual-luciferase reporter assay (HIF-1α→STC2 promoter), siRNA knockdown/overexpression, transcriptomic profiling, immune deconvolution (CIBERSORT) Cellular signalling Medium 42217552
2025 FUT3-mediated fucosylation of GRP78 triggers downstream ER stress signaling and activates the PERK/ATF4/STC2 pathway, thereby enhancing CRC cell survival under glucose-deficient conditions; this places STC2 as a downstream effector of the PERK/ATF4 ER stress axis. MeRIP-seq context, co-IP (FUT3-GRP78), Western blot, pathway inhibition/activation experiments under glucose restriction, in vitro and in vivo assays NPJ precision oncology Low 41392296

Source papers

Stage 0 corpus · 64 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Molecular cloning of a second human stanniocalcin homologue (STC2). Biochemical and biophysical research communications 100 9753616
2016 STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways. Oncotarget 83 27662663
2023 STC2 activates PRMT5 to induce radioresistance through DNA damage repair and ferroptosis pathways in esophageal squamous cell carcinoma. Redox biology 78 36764215
2022 Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target. Journal of experimental & clinical cancer research : CR 76 35501821
2017 Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. Materials science & engineering. C, Materials for biological applications 69 29208281
2017 STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget 61 27863406
2010 STC2: a predictive marker for lymph node metastasis in esophageal squamous-cell carcinoma. Annals of surgical oncology 56 20734150
2019 Long non-coding RNA HOTAIR/microRNA-206 sponge regulates STC2 and further influences cell biological functions in head and neck squamous cell carcinoma. Cell proliferation 55 31297902
2012 STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro. BMB reports 53 23187001
2015 Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease. Molecular oncology 52 25771305
2019 Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. International journal of cancer 50 31162839
2014 Stanniocalcin-2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and progression. Biochimica et biophysica acta 45 25463045
2019 Downregulation of LINC00460 decreases STC2 and promotes autophagy of head and neck squamous cell carcinoma by up-regulating microRNA-206. Life sciences 40 31075234
2019 MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer. European review for medical and pharmacological sciences 39 31696489
2016 STC2 as a novel mediator for Mus81-dependent proliferation and survival in hepatocellular carcinoma. Cancer letters 35 27939696
2019 Upregulation of STC2 in colorectal cancer and its clinicopathological significance. OncoTargets and therapy 33 30863092
2015 STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer. Oncology reports 33 26165228
2019 Effect of STC2 gene silencing on colorectal cancer cells. Molecular medicine reports 30 31173256
2019 Stanniocalcin 2 (STC2) expression promotes post-radiation survival, migration and invasion of nasopharyngeal carcinoma cells. Cancer management and research 30 31372045
2023 LncRNA NEAT1 inhibits apoptosis and autophagy of ovarian granulosa cells through miR-654/STC2-mediated MAPK signaling pathway. Experimental cell research 26 36634743
2022 Long non-coding RNA MAFG-AS1 promotes proliferation and metastasis of breast cancer by modulating STC2 pathway. Cell death discovery 20 35513366
2020 STC2 modulates ERK1/2 signaling to suppress adipogenic differentiation of human bone marrow mesenchymal stem cells. Biochemical and biophysical research communications 16 31982135
2021 SNHG17 Serves as an Oncogenic lncRNA by Regulating the miR-361-3p/STC2 Axis in Rectal Cancer. Frontiers in genetics 14 34249085
2020 miR-381 Mediates the Development of Head and Neck Squamous Cell Carcinoma via Targeting STC2. OncoTargets and therapy 14 32547079
2023 Circ-STC2 promotes the ferroptosis of nucleus pulposus cells via targeting miR-486-3p/TFR2 axis. Journal of orthopaedic surgery and research 13 37480032
2023 STC2 is a potential biomarker of hepatocellular carcinoma with its expression being upregulated in Nrf1α-deficient cells, but downregulated in Nrf2-deficient cells. International journal of biological macromolecules 12 37866563
2020 MiR-184 Combined with STC2 Promotes Endometrial Epithelial Cell Apoptosis in Dairy Goats via RAS/RAF/MEK/ERK Pathway. Genes 12 32906580
2020 Long noncoding RNA ROR1-AS1 enhances STC2-mediated cell growth and autophagy in cervical cancer through miR-670-3p. Journal of receptor and signal transduction research 12 33081599
2022 Light-driven Oxidative Demethylation Reaction Catalyzed by a Rieske-type Non-heme Iron Enzyme Stc2. ACS catalysis 10 37168530
2025 LCORL and STC2 Variants Increase Body Size and Growth Rate in Cattle and Other Animals. Genomics, proteomics & bioinformatics 9 40094447
2022 Structural insights into the covalent regulation of PAPP-A activity by proMBP and STC2. Cell discovery 9 36550107
2023 Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma. Heliyon 8 37389061
2022 Hepatitis B virus X protein promotes hepatocarcinogenesis via the activation of HMGA2/STC2 signaling to counteract oxidative stress-induced cell death. Carcinogenesis 8 35353897
2020 BIRC7 and STC2 Expression Are Associated With Tumorigenesis and Poor Outcome in Extrahepatic Cholangiocarcinoma. Technology in cancer research & treatment 8 33234031
2024 STC2 knockdown inhibits cell proliferation and glycolysis in hepatocellular carcinoma through promoting autophagy by PI3K/Akt/mTOR pathway. Archives of biochemistry and biophysics 7 39271096
2023 The STC2-PAPP-A-IGFBP4-IGF1 axis and its associations to mortality and CVD in T2D. Endocrine connections 7 36607154
2013 Comparative study of clinicopathological significance, BIRC7, and STC2 expression between squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladder. Neoplasma 6 23906305
2025 Fine particulate matter exacerbates asthma by activating STC2-mediated mitophagy through METTL3/YTHDF2-dependent m6A methylation. Journal of hazardous materials 5 40499413
2023 The proliferation and angiogenesis in hemangioma-derived endothelial cells is affected by STC2 medicated VEGFR2/Akt/eNOS pathway. Pakistan journal of medical sciences 5 37492297
2024 STC2 suppresses triple-negative breast cancer migration and invasion by inhibition on EMT and promotion on cell apoptosis. Discover oncology 4 39117970
2021 Research progress of STC2 in breast cancer. Biophysics reports 4 37287492
2020 In Vivo Gene Delivery of STC2 Promotes Axon Regeneration in Sciatic Nerves. Molecular neurobiology 4 33011858
2020 Chronic Venous Disease Patients Showed Altered Expression of IGF-1/PAPP-A/STC-2 Axis in the Vein Wall. BioMed research international 4 33381575
2025 Dissecting the METTL3/STC2 axis in colorectal cancer: implications for drug resistance and metastasis. Cell biology and toxicology 3 40494964
2024 STC2 Inhibits Hepatic Lipid Synthesis and Correlates with Intramuscular Fatty Acid Composition, Body Weight and Carcass Traits in Chickens. Animals : an open access journal from MDPI 3 38338026
2024 miR-34b-3p-mediated regulation of STC2 and FN1 enhances chemosensitivity and inhibits proliferation in cervical cancer. Acta biochimica et biophysica Sinica 3 38477044
2023 Osteosarcoma transcriptome data exploration reveals STC2 as a novel risk indicator in disease progression. BMC medical genomics 3 36803385
2023 The down-regulation of STC2 mRNA may serve as a biomarker for death from mechanical asphyxia. Legal medicine (Tokyo, Japan) 2 38159418
2025 Smoking-Induced STC2+ Tumor Cells Drive Tumor-Vascular Crosstalk in Laryngeal Squamous Cell Carcinoma via Spatial and Single-Cell Transcriptomics. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 1 41203580
2024 Pregnancy associated plasma protein-A2 (PAPP-A2) and stanniocalcin-2 (STC2) but not PAPP-A are associated with circulating total IGF-1 in a human adult population. Scientific reports 1 38245583
2024 Photo-reduction facilitated stachydrine oxidative N-demethylation reaction: A case study of Rieske non-heme iron oxygenase Stc2 from Sinorhizobium meliloti. Methods in enzymology 1 39260999
2024 [Corrigendum] Effect of STC2 gene silencing on colorectal cancer cells. Molecular medicine reports 1 39513596
2026 STC2 promotes anoikis resistance by modulating TGIF1 mRNA stability in colorectal cancer. Frontiers in cell and developmental biology 0 41696444
2026 STC2 promotes colorectal cancer progression via c-Myc-mediated glycolysis and the PI3K/AKT/mTOR pathway. Discover oncology 0 41843316
2026 STC2-mediated calcium homeostasis dysregulation in the osteosarcoma microenvironment: Insights from single-cell sequencing and machine learning. Translational oncology 0 41985319
2026 Single-cell transcriptomics reveals glycolytic heterogeneity and identifies STC2 as a key regulator of metabolic reprogramming in osteosarcoma. Molecular and cellular biochemistry 0 42166004
2026 STC2 mediates hypoxia-induced immunosuppression and tumorigenesis in hepatocellular carcinoma. Cellular signalling 0 42217552
2025 STC2 regulates the proliferation, migration and glycolysis of glioma cells through modulating ITGB2. Metabolic brain disease 0 40126711
2025 Animal study on stanniocalcin 2 (STC2) and gastric cancer metastasis: discussing possible molecular mechanisms. JPMA. The Journal of the Pakistan Medical Association 0 41248659
2025 ATF4 transcriptional regulation of OMD and STC2 drives vascular calcification progression via the PI3K/AKT pathway. Pathology, research and practice 0 41274065
2025 FUT3 mediated GRP78 fucosylation promotes colorectal cancer survival and proliferation under glucose restriction via PERK/ATF4/STC2 axis. NPJ precision oncology 0 41392296
2025 STC2 Serves as a Critical Hypoxic Effector in Keloid Pathogenesis by Orchestrating Fibroblasts Activation and ECM Remodelling. Experimental dermatology 0 41408929
2023 Evaluating STC2 gene RNA in peripheral blood serum of gastric cancer patients. Cellular and molecular biology (Noisy-le-Grand, France) 0 38063115
2019 Erratum: Stanniocalcin 2 (STC2) Expression Promotes Post-Radiation Survival, Migration and Invasion of Nasopharyngeal Carcinoma Cells [Corrigendum]. Cancer management and research 0 31853197

Missed literature

Know a paper Affinage missed for STC2? Flag it for the maintainers and the community.

No submissions yet.